^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TNG260

    i
    Company:
    Tango Therap
    Drug class:
    RCOR1 inhibitor
    Related drugs:
    22d
    Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors (clinicaltrials.gov)
    P1/2, N=126, Recruiting, Tango Therapeutics, Inc. | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial primary completion date • IO biomarker
    |
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    |
    Keytruda (pembrolizumab) • TNG260
    almost2years
    Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors (clinicaltrials.gov)
    P1/2, N=126, Recruiting, Tango Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • IO biomarker • Metastases
    |
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    |
    Keytruda (pembrolizumab) • TNG260
    almost2years
    Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors (clinicaltrials.gov)
    P1/2, N=126, Not yet recruiting, Tango Therapeutics, Inc.
    New P1/2 trial • Combination therapy • IO biomarker • Metastases
    |
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    |
    Keytruda (pembrolizumab) • TNG260
    2years
    TNG260: A novel, orally active, CoREST-selective deacetylase inhibitor for the treatment of STK11-mutant cancers (AACR 2023)
    Unlike previously developed pan-HDAC inhibitors, which are directly cytotoxic to cancer (and immune) cells, IND-enabling toxicology studies in rat and dog showed that TNG260 was well-tolerated at exposures predicted to be efficacious in humans, with bone marrow suppression only detectable at doses where TNG260 is no longer selective for CoREST inhibition. TNG260 clinical development will be among the first to combine the power of genetic patient selection and immunotherapy, evaluating patients with STK11 mutant cancers in a trial combining TNG260 and a checkpoint inhibitor.
    PD(L)-1 Biomarker • IO biomarker
    |
    STK11 (Serine/threonine kinase 11) • HDAC1 (Histone Deacetylase 1) • HDAC3 (Histone Deacetylase 3)
    |
    STK11 mutation
    |
    TNG260
    over2years
    TNG260, a CoREST-selective deacetylase inhibitor, reverses anti-PD1 resistance driven by loss of STK11 (SITC 2022)
    It reverses the immune evasion phenotype caused by loss of STK11 and induces tumor regressions in an STK11-mutant model in combination with α-PD1. The TNG260 clinical development plan will be among the first to combine the power of genetic patient selection and immunotherapy, evaluating patients with STK11 mutant cancers in a trial combining TNG260 and a checkpoint inhibitor.
    PD(L)-1 Biomarker • IO biomarker
    |
    STK11 (Serine/threonine kinase 11) • HDAC3 (Histone Deacetylase 3)
    |
    STK11 mutation
    |
    TNG260 • Undisclosed immune evasion therapeutic